Navigation Links
Diabetes drug supported by Mexican Diabetes Federation

VANCOUVER, June 21, 2007 /PRNewswire-FirstCall/ - Biotech Holdings reports that the Mexican Diabetes Federation has given Biotech's "Sucanon" diabetes drug its support in an overview of diabetic drugs published in the May-June 2007 issue of Diabetes Hoy, the Diabetic Federation's scientific and medical magazine for doctors and other health professionals.

The overview of diabetic drugs, written by Dr. Roberto Cepeda Gonzalez, Medical Director of the Specialized Center for Diabetes, in Mexico City, notes that Sucanon falls in a category of diabetic drugs known as "insulin sensitizers" for their action in making the body's cells more sensitive to circulating insulin. The review (see Endorsements at http://www.sucanonhealth.com/section.asp?pageid=4107) notes that the most widely used insulin sensitizers belong to a family of drugs known as thiazolidinediones or glitazones.

The glitazone drugs, the review notes, have a history of problems in contrast with Sucanon which, clinical studies have indicated, is very safe. The review notes that Sucanon does not have any of the hepatotoxicity or liver-damage risks of the glitazone drugs. The first glitazone, troglitazone was approved in 1998 but was withdrawn shortly thereafter. Two additional glitazones - rosiglitazone and pioglitazone - have recently been targeted with a "black box" warning by the U.S. FDA due to concerns related to cardiac risk when taking these drugs (see http://www.msnbc.msn.com/id/19090626/).

The review in Diabetes Hoy also notes that another widely used Type II Diabetes medication, metformin, presents risks for patients with compromised kidney function, frequently a symptom of Type II Diabetes.

Sucanon, which received regulatory approval in Mexico in 2004, is widely sold in that country on a non-prescription basis through a range of retailers including Costco and Walmart.

Sucanon is now also available without prescription to diabetics in countries worldwide, including the U.S. and Canada, which permit import of otherwise-unavailable drugs for direct personal use. To order Sucanon, see www.Sucanonhealth.com.

This release has been approved by the Board of Directors of Biotech Holdings.

    The TSX Venture Exchange does not accept responsibility for the adequacy

    or accuracy of this release.


    Robert B. Rieveley, Pres.

    On behalf of the Board of Directors

Any statements made in this release that are not based on historical fact are forward-looking statements. Any forward-looking statements made in this release represent management's best judgement as to what may occur in the future. However, actual outcome and results are not guaranteed and are subject to certain risks, uncertainties and assumptions and may differ materially from what is expressed.

If you wish to be removed from Biotech Holdings' email news distribution list, please reply by email, putting "remove" in the subject line.

CONTACT: Austin Rand at Biotech Holdings, 1-888-216-1111 (toll-free) 8 a.m. to 4 p.m. Pacific time. For background information on Biotech Holdings, or to receive news updates, see www.biotechltd.com. The company can be reached by calling (604) 295-1119

CONTACT: Austin Rand at Biotech Holdings, 1-888-216-1111 (toll-free) 8a.m. to 4 p.m. Pacific time. For background information on BiotechHoldings, or to receive news updates, see www.biotechltd.com. The companycan be reached by calling (604) 295-1119

Ticker Symbol: (:BIO.),(NASDAQ-OTCBB:BIOHF)

Terms and conditions of use apply
Copyr ight © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Diagnosing Diabetes: Immediate HbA1c Results Improve Glycemic Control
2. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
3. Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic Control in Subjects with Type 2 Diabetes Compared to Metformin Alone
4. Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic Control in Subjects with Type 2 Diabetes Compared to Metformin Alone
5. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
6. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
7. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
8. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
9. Lipitor Reduced the Risk of Coronary Events by Half and Stroke by Nearly One-Third in High-Risk Patients with Type 2 Diabetes Who Experienced a Recent Stroke
10. Sangamo BioSciences Announces Presentation of Phase 1 ZFP Therapeutic Data at American Diabetes Association Meeting
11. Phase IIIb Clinical Data Validate the Overall and Cardiovascular Safety Profile of Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) in Patients with Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)...   Pulmatrix, Inc ., (NASDAQ: PULM ... announced today that it was added to the Russell ... comprehensive set of U.S. and global equity indexes on ... milestone for Pulmatrix," said Chief Executive Officer Robert ... progress in developing drugs for crucial unmet medical needs, ...
(Date:6/23/2016)... Research and Markets has announced the addition of ... report to their offering. ... kidney failure, it replaces the function of kidneys by removing ... thus the treatment helps to keep the patient body,s electrolytes ... Increasing number of ESRD patients & substantial healthcare expenditure ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: ... 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) assay ... sepsis or septic shock. With this clearance, Roche is ... a fully integrated solution for sepsis risk assessment and ... with bacterial infection and PCT levels in blood can ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... ... PawPaws brand pet supplements owned by Whole Health Supply is ... of felines. The formula is all-natural and is made from Chinese herbs that have ... Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia Root Extract ...
(Date:6/25/2016)... , ... June 25, 2016 , ... ... policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at ... on several important health care topics including advance care planning, healthcare costs and ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... "With 30 ... their specific project," said Christina Austin - CEO of Pixel Film Studios. , ... and all within Final Cut Pro X . Simply select a ProHand generator ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. ... from injury. Recently, he has implemented orthobiologic procedures as a method for treating ... one of the first doctors to perform the treatment. Orthobiologics are substances that ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... A recent ... that most people are unfamiliar with. The article goes on to state that individuals ... also many of these less common operations such as calf and cheek reduction. The ...
Breaking Medicine News(10 mins):